NVO logo

Novo Nordisk A/S (NVO)

$40.31

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVO

Market cap

$178.49B

EPS

3.62

P/E ratio

10.8

Price to sales

3.57

Dividend yield

2.871%

Beta

0.694454

Price on NVO

Previous close

$40.30

Today's open

$39.76

Day's range

$39.53 - $40.55

52 week range

$35.12 - $64.16

Profile about NVO

CEO

Maziar Mike Doustdar

Employees

68800

Headquarters

Bagsvaerd,

Exchange

New York Stock Exchange

Shares outstanding

4.43B

Issue type

American Depository Receipt

NVO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NVO

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures Additional real-world data from a separate analysis found people initiating semaglutide 2.4 mg had greater one-year reductions in liver enzymes and weight, plus a larger HbA1c decrease, versus those not initiating treatment with semaglutide 2.4 mg PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2026 /PRNewswire/ -- Novo Nordisk today announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once weekly injection use versus those not initiating treatment with semaglutide 2.4 mg and liver and cardiometabolic outcomes in adults with metabolic dysfunction-associated steatohepatitis (MASH).

news source

PRNewsWire • 17 hours ago

news preview

Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income

Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis. Projected annualized returns exceed 18% through 2030, underpinned by expanding oral GLP-1 market share and pipeline momentum.

news source

Seeking Alpha • Nov 6, 2026

news preview

NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook

Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Novo Nordisk Q3 profit beats forecast; raises 2026 guidance

Obesity drugmaker Novo Nordisk raised its 2026 outlook for the third time this year ​on Wednesday as quarterly sales of its Wegovy pill beat forecasts, bolstering the Danish firm's efforts to recover ground lost to US rival Eli ‌Lilly.

news source

Reuters • Nov 4, 2026

news preview

Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues

The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.

news source

WSJ • Nov 4, 2026

news preview

Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know

Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next year's sales and three hurting them.

news source

The Motley Fool • Nov 4, 2026

news preview

Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone

Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices fall and a rival closes in.

news source

24/7 Wall Street • Nov 4, 2026

news preview

Novo Nordisk stock jumps as Wegovy pill sales beat estimates

Novo Nordisk shares NVO rallied on Wednesday after the Danish drugmaker reported stronger-than-expected third-quarter results, driven by demand for its Wegovy weight-loss pill, and raised its full-year outlook for the third time this year. The company's American depositary receipts rose as much as 5.36% to $42.36, recovering some ground after falling more than 20% this year through Tuesday's close.

news source

Invezz • Nov 4, 2026

news preview

Novo Nordisk's CFO Karsten Munk Knudsen to leave company

Novo Nordisk said on Wednesday its ​Chief ​Financial Officer Karsten ‌Munk ⁠Knudsen would step down and ​that ​Luigi ⁠La Corte ​would join ​as ⁠its new CFO.

news source

Reuters • Nov 4, 2026

news preview

Novo Nordisk: 3 Key Takeaways for Long-Term Investors

Novo Nordisk added 1.3 million patients in the third quarter. Wegovy pill will reach over 20 markets by mid-2027.

news source

The Motley Fool • Nov 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Novo Nordisk A/S

Open an M1 investment account to buy and sell Novo Nordisk A/S commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVO on M1